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IDITORIAL COMMENT
on’t Blame the Stents*
eorge W. Vetrovec, MD
ichmond, Virginia
iabetes mellitus portends excessive adverse clinical out-
omes for coronary artery disease (CAD) patients, including
hose undergoing percutaneous coronary intervention (PCI)
1–5). Causes for adverse outcomes in diabetic patients
nclude more stent hyperplasia (3), smaller vessels, greater
ascular inflammation, a higher thrombotic state, type of
iabetic treatment (oral vs. insulin), and severe diffuse
ascular disease promoted by more risk factors, with a
arked increase in the relative adverse impact on outcome
or each risk factor. Furthermore, the outcomes of diabetic
atients with CAD indicate that eliminating ischemia
aused by a finite number of focal stenoses is not sufficient.
evascularization reduces angina as well as morbidity and
ortality, particularly in high-risk patients. However, future
vents are more often related to progressive CAD, often the
esult of non-critical lesions observed during earlier angiog-
aphy (1).
See page 1348
The potential for multivessel PCI to be a competitor of
oronary artery bypass grafting (CABG) early on led to
andomized trials demonstrating equivalent survival out-
omes for balloon PCI compared with CABG. However,
atients undergoing PCI frequently required additional
evascularization later in the year compared with CABG
atients. However, the Bypass Angioplasty Revasculariza-
ion Investigation (BARI) (4,5) and Emory Angioplasty
ersus Surgery Trial (EAST) (6) trials demonstrated that
alloon angioplasty in treated diabetic patients was associ-
ted with increased mortality at five and eight years,
espectively, compared with CABG. These results form the
asis for the generally accepted recommendation that, when
easible, CABG is preferable to PCI in treated diabetic
atients with multivessel CAD.
More recently the impact of coronary stents, with their
otential for more durable revascularization, has been in-
estigated. Data from the Arterial Revascularization Ther-
pies Study (ARTS) trial (7), which randomized over 1,200
atients with multivessel disease to stenting or CABG,
emonstrated a nearly 20% absolute reduction in the need
or late revascularization in the stented patients compared
ith earlier balloon PCI studies. Overall, one-year mortality
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiology, Virginia Commonwealth University, Richmond,tirginia.as not different between PCI using one or more stents and
ABG. In a sub-analysis, diabetic patients (not prospec-
ively randomized) had a higher rate of repeat revascular-
zation compared with CABG or non-diabetic stent pa-
ients (8). However, mortality at one year tended (but not
ignificantly) to be greater for diabetic (6.3%) versus CABG
atients (3.1%). However, the ARTS trial also emphasizes
he overt risk of diabetes regardless of the form of revascu-
arization. Patients undergoing CABG had a significantly
ncreased risk of peri-surgical events, markedly affecting
linical outcome and cost. Re-hospitalizations for diabetic
ABG patients were significantly increased, relating to
on-revascularization events such as sternal infection,
troke, renal insufficiency, and pulmonary embolism. Thus,
he net cost advantage at one year was still in favor of coronary
tenting, partly related to morbid CABG complications de-
pite more revascularization procedures in the stent PCI
iabetic group. These results re-emphasize the adverse effects
f diabetes on both CABG and stent PCI outcome.
IMITS OF FOCAL REVASCULARIZATION
he complexity of diffuse diabetic CAD on the outcome of
CI versus CABG was described in the diabetic subgroup
f the randomized CABG versus balloon angioplasty trial
Coronary Angioplasty vs. Bypass Revascularization Inves-
igation [CABRI]) (9). In this trial, although mortality was
ignificantly higher for the balloon PCI group compared
ith the CABG group, the mortality for the diabetic versus
on-diabetic patients who underwent CABG was also twice
s high. Of note, the number of successfully revascularized
esions was nearly twice as great for the CABG population
ompared with the angioplasty group. Reasons for less
omplete revascularization in angioplasty patients is partially
echnical, although this limitation continues to decline with
dvances in equipment. Conversely, a bypass graft that
overs multiple lesions of varying severity, including the
ost critical lesion, which may have been the only lesion
reated with the angioplasty, “protects” a longer segment of
he artery at risk for future coronary events. The extent of
vascular protection” may account for a significant compo-
ent of the CABG advantage in diabetics who tend to have
ore diffuse disease. Again, in the more recent ARTS trial
7), complete revascularization was more commonly ob-
erved with CABG than with stenting (10). Although the
xtent of revascularization at one year did not predict
vent-free survival, stented patients with less complete
evascularization were more likely to need subsequent
ABG. Thus, completeness of revascularization, including
oth significant lesions as well as multiple, often non-critical
esions, appears to effect late outcome.
ONTEMPORARY STENTING
n the report by Mehran et al. (11) published in this issue of
he Journal, the authors describe the short-term and one-
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Editorial Comment April 21, 2004:1355–7ear outcomes for patients undergoing multivessel native
essel stenting, specifically comparing diabetic with non-
iabetic patients. In this report, the authors included a small
umber of non-treated diabetic patients in the non-diabetic
roup as reported in the BARI trial (6). Overall, the
opulation included 689 patients with 1,639 native coronary
esions, including 188 diabetic patients with 439 treated
esions. Short-term outcomes were similar between the
iabetic and non-diabetic groups, except for a higher inci-
ence of CABG in the insulin-dependent diabetic group
3.5%) versus 1% or less for non-diabetics or oral treatment
iabetics. However, CABG risk represents only 3 patients
f 86; and such small numbers could easily explain this
ifference. More importantly, the one-year results demon-
trate a 10% lower survival in treated diabetic patients
ompared with non-diabetic patients. Likewise, the inci-
ence of target lesion revascularization for the oral agent
nd insulin-dependent diabetic groups was 26% and 35%,
espectively, compared with 16% in non-diabetics, a number
onsistent with what would be predicted for a multivessel
tent population.
Importantly, in this study, the diabetic patients, particu-
arly the insulin-dependent patients, experienced more renal
ailure than did non-diabetic patients, which is a known
redictor of high, short-term risk after PCI and CABG.
ther characteristics increasing the overall risk of the
iabetic population included relatively small vessels based
n pretreatment reference vessel size, with more insulin-
ependent diabetic patients having more than three lesions
tented. The diabetic patients had more incidents of hyper-
ension, peripheral vascular disease, a higher incidence of
rior cerebrovascular events, and greater clinical congestive
eart failure. The increased risk profile of the diabetic
opulation was further supported by a comparatively high
ncidence (33%) of patients with a reduced left ventricular
jection fraction (50%), a rate that is higher than in the
ARI trial (6).
Although the diabetic patients in this study had greater
estenosis, this may be related to smaller vessel size, greater
isk factors, but also to the independent effect of diabetes
1–5). Furthermore, the need for late target lesion revascu-
arization in the treated diabetic patients may be related to
isease progression other than in the stented segments.
omorbidities may have increased target vessel, not target
esion risk, because the event rate for renal failure patients
as increased, whereas the target lesion revascularization
as not.
ONFOUNDING CLINICAL ISSUES
rospective registry studies have the advantage of real-world
utcomes because they represent practice reality, but they
lso have the limitation of uncontrolled and undocumented
eal world inconsistencies in practice, some of which may
epresent less than optimal risk management by multiple
ractitioners involved in the long-term medical care. Con- mersely, the outcomes reported may have been benefited by
he decision-making capability of the operators (12,13). For
xample, in the EAST trial (13), operator decisions in the
egistry population were associated with better outcomes
han in randomized patients.
Although PCI was performed by experienced operators in
he current report, the outcome may have been affected by
ncontrolled technical aspects, such as variable stent design
se and deployment methods, including maximum inflation
ressures, predilation, and so forth. The inconsistent appli-
ation of multiple stent designs and techniques over six years
ay have had an unknown effect, particularly in higher-risk
esions, which may be more responsive to specialized stent
haracteristics or procedure-related techniques. Thus, tech-
ical variability may have produced either a positive or
egative advantage in some patient populations.
DJUNCTIVE MEDICAL TREATMENT
he authors (11) report a10% use of IIb/IIIa antagonists,
hich may relate to the high (28%) incidence of periproce-
ure myocardial infarction. Abciximab use has been shown
o significantly reduce acute and long-term events for
iabetic patients undergoing stent placement (14). System-
tic use of IIb/IIIa antagonists might have significantly
arrowed the gap between diabetic and non-diabetic pa-
ients.
Another factor not reported is the overall use of statin
herapy, which became more recognized for its benefits over
he time of the study. Although the LIPS trial (15) did not
how a difference in outcome for patients after angioplasty
reated with fluvastatin at one year, favorable effects were
vident beginning at 1.5 years, particularly in diabetics and
atients with multivessel disease. Furthermore, although
atients with acute myocardial infarction within 48 hours
ere excluded from the Mehran et al. report (11), the
ercentage of patients with acute coronary syndromes was
ot defined. Statins improve outcomes in acute coronary
yndromes, as evidenced by the Myocardial Ischemia Re-
uction with Aggressive Cholesterol Lowering (MIRACL)
16) trial. Although the MIRACL trial did not address
oronary intervention specifically, the favorable effect on
hort-term outcome further suggests that statins can signif-
cantly impact vascular inflammation, which appears to be
ne of the hallmarks of diabetic vascular disease.
Relative to other risk factors, hypertension was higher in
he diabetic population. Again, given the time frame of the
tudy, the unknown degree of hypertension control (current
uidelines call for blood pressures of 130/80 mm Hg for
iabetes) may have had an important adverse impact on
utcome.
Another issue under intense current investigation is the
ptimal drug treatment of glucose control in diabetes to
ptimize late outcome. In the current registry, diabetes
anagement was uncontrolled regarding type of treatment
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April 21, 2004:1355–7 Editorial Commentnd/or effectiveness in the absence of the hemoglobin A1C
evels achieved.
Finally, recently reported one-year results of the CREDO
rial (17) demonstrated a 26.9% (absolute 3%) reduction in
ombined death, myocardial infarction, or stroke for con-
inued clopidogrel treatment beyond one month after PCI.
imilar results applied to the Mehran et al. (11) population
ould have further improved outcome had this information
een available during the study period.
In summary, clearly defined, standardized adjunctive
edical therapy might have had significant impact on the
utcome of described patient population, partially relating
o the stent vascular response, but more likely directed at
lunting the generalized adverse vascular effects associated
ith diabetes.
HE FUTURE
rug-eluting stents should further improve the late outcomes
f patients undergoing multivessel coronary intervention. On
he other hand, data from the Sirolimus-Eluting Stents versus
tandard Stents in Patients with Stenosis in a Native Coronary
rtery (SIRIUS) trial (18) indicates that although diabetic
estenosis is reduced significantly compared with a control
estenosis with the DES stent tends to still be higher than for
on-diabetic patients. Furthermore, in the SIRIUS trial, nine-
onth follow-up showed a 7% to 8.6% risk in the sirolimus
nd control stent groups, respectively, for non-restenotic
vents, such as in-hospital major adverse coronary events and
ut-of-hospital myocardial infarction, mortality, and late non-
arget lesion revascularization.
In the era of drug-eluting stents, there is no doubt that
etter outcomes will be seen as a result of more durable
evascularization, but the need for targeted adjunctive med-
cal therapy for the entire vasculature remains crucial for
ptimal outcomes. Diabetics will be the major group to
enefit from a better understanding of vascular disease
anagement, including risk factors, thrombosis, and plate-
ets as well as optimal methods for glucose control.
In summary, the data presented by Mehran et al. (11) are
ncouraging in that stents did improve the outcome for
ultivessel PCI compared with prior balloon trials. The
esults also emphasize that optimal diabetic management is
omplex and incompletely treated by stent revascularization
lone. This is not a failure of stents as much as it is a failure
f our understanding and application of effective adjunctive
ascular therapy. However, the future is bright with drug-
luting stents poised to markedly limit restenosis while the
pplication of medical vascular management continues to
xpand.
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80036, Richmond, Virginia 23298-0036. E-mail: gvetrove@
sc.vcu.edu.EFERENCES
1. Mathew V, Holmes DR. Outcomes in diabetics undergoing revascu-
larization: the long and the short of it. J Am Coll Cardiol 2002;40:
424–7.
2. Srinivas VS, Brooks MM, Detre KM, et al. Contemporary percuta-
neous coronary intervention versus balloon angioplasty for multivessel
coronary artery disease: a comparison of the National Heart, Lung and
Blood Institute Dynamic Registry and the Bypass Angioplasty Revas-
cularization Investigation (BARI) study. Circulation 2002;1061627–
33.
3. Van Belle E, Perie M, Braune D, et al. Effects of coronary stenting on
vessel patency and long-term clinical outcome after percutaneous
coronary revascularization in diabetic patients. J Am Coll Cardiol
2002;40:410–7.
4. The Bypass Angioplasty Revascularization Investigation (BARI) In-
vestigators. Comparison of coronary bypass surgery with angioplasty in
patients with multivessel disease. N Engl J Med 1996;335:217–25.
5. The BARI Investigators. Influence of diabetes on 5-year mortality and
morbidity in a randomized trial comparing CABG and PTCA in
patients with multivessel disease. Circulation 1997;96:1761–9.
6. King SB, Kosinski AS, Guyton RA, et al. Eight-year mortality in the
Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol
2000;35:1116–21.
7. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery
bypass surgery and stenting for the treatment of multivessel disease.
N Engl J Med 2001;344:1117–24.
8. Abizaid A, Costa MA, Centemero M, et al. Clinical and economic
impact of diabetes mellitus on percutaneous and surgical treatment of
multivessel coronary disease patients: insights from the Arterial Re-
vascularization Therapy Study (ARTS) trial. Circulation 2001;104:
533–8.
9. Kurbaan AS, Bowker TJ, Ilsley CD, et al., for the CABRI investiga-
tors. Difference in the mortality of the CABRI diabetic and nondia-
betic populations and its relation to coronary artery disease and the
revascularization mode. Am J Cardiol 2001;87:947–50.
0. Van den Brand MJ, Rensing BJ, Morel MA, et al. The effect of
completeness of revascularization on event-free survival at one year in
the ARTS Trial. J Am Coll Cardiol 2002;39:559–64.
1. Mehran R, Dangas GD, Kobayashi Y, et al. Short- and long-term
results after multivessel stenting in diabetic patients. J Am Coll
Cardiol 2004;43:1348–54.
2. Detre KM, Guo P, Holubkov R, et al. Coronary revascularization in
diabetic patients: a comparison of the randomized and observational
components of the Bypass Angioplasty Revascularization Investigation
(BARI). Circulation 1999;99:633–40.
3. King SB, Barnhart HX, Kosinski AS, et al. Angioplasty or surgery for
multivessel coronary artery disease: comparison of eligible registry and
randomized patients in the EAST trial and influence of treatment
selection on outcomes. Emory Angioplasty versus Surgery Trial
Investigators. Am J Cardiol 1997;79:1453–9.
4. Bhatt DL, Marso SP, Lincoff AM, et al. Abciximab reduces mortality
in diabetics following percutaneous coronary intervention. J Am Coll
Cardiol 2000;35:922–8.
5. Surruys PW, deFeyter P, Macaya C, Kokott N, et al. Fluvastatin for
prevention of cardiac events following successful first percutaneous
coronary intervention: a randomized controlled trial. JAMA 2002;287:
3215–22.
6. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorva-
statin on early recurrent ischemic events in acute coronary syndromes:
the MIRACL study: a randomized controlled trial. JAMA 2001;285:
1711–8.
7. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral
antiplatelet therapy following percutaneous coronary intervention: a
randomized controlled trial. JAMA 2002;288:2411–20.
8. Moses JW, Leon MB, Popma JJ, et al. for the SIRIUS investiga-
tors. Sirolimus-Eluting Stents versus Standard Stents in Patients
with Stenosis in a Native Coronary Artery. N Engl J Med
2003;349:1315–23.
